PAK6: a potential anti-cancer target

Authors

  • Chan-Chan Gong Xuzhou Medical University, Department of Pathology
  • Tong-Tong Li Xuzhou Medical University, Department of Pathology
  • Dong-Sheng Pei Xuzhou Medical University, Department of Pathology https://orcid.org/0000-0002-8053-3741

DOI:

https://doi.org/10.1590/s2175-97902019000318315

Keywords:

PAK6, androgen Receptor (AR), cancer therapy, miRNAs

Abstract

p21-activated kinase 6 (PAK6) is a member of the PAK family of serine/threonine kinases that are known effectors of Rho GTPases Cdc42 and Rac. PAKs regulate a large number of complex cellular mechanisms, including cell motility, morphology, and tumor development. PAK6, initially cloned as an interacting partner of the androgen receptor (AR), is associated with an array of cellular processes implicated in tumor progression. However, the full biological implications of PAK6 activity during cancer remain poorly understood. In this review, we assess our current understanding of the physiological roles of classical PAK6 functionality in mammals, in addition to its emerging role in tumorigenesis.

Downloads

Downloads

Published

2020-12-09

Issue

Vol. 56 (2020)

Section

Review

License

Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.

The on-line journal has open and free access.

How to Cite

PAK6: a potential anti-cancer target. (2020). Brazilian Journal of Pharmaceutical Sciences, 56, e18315. https://doi.org/10.1590/s2175-97902019000318315